 Assembly Biosciences Inc NASDAQ: ASMB will not initiate Phase 3 studies of vebicorvir VBR, or ABI-H0731 as a chronic suppressive therapy CST, as the company wants to focus on hepatitis B therapies. The CST study was supposed to be conducted with BeiGene Ltd NASDAQ: BGNE, which licensed the rights to VBR in China. 